Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Primary Peritoneal Endometrioid Adenocarcinoma
Mayo Clinicgene_therapyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Primary Peritoneal Endometrioid Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Ohio State University Comprehensive Cancer Center | Phase 3 | B |
Olaparib NRG Oncology | Phase 3 | B |
(+)-VINCRISTINE NRG Oncology | Phase 3 | B |
Irinotecan NRG Oncology | Phase 3 | B |
View all 21 →
Same molecule, other indications
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →